by Elena Iemma | Feb 17, 2021 | News
PROVIDENCE, RI, February 17, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) today announces its participation in the INDIGO consortium – a partnership of public and private research and development organizations from the EU, India, and United States (funded by the...
by Adam | Dec 15, 2020 | News
PROVIDENCE, RI, December 15, 2020 /PRNewswire/ — EpiVax, Inc. reports a record-breaking year for the “ISPRI” immunogenicity screening toolkit. More pharmaceutical and biotechnology companies signed new and continuing licenses for access to the toolkit in 2020...
by Annie De Groot | Nov 16, 2020 | Events
Dr. Anne De Groot will be participating in the 8th annual AIS “Multispecific Abs, Ab-like molecules and adoptive cell therapy for fighting diseases” Dr. De Groot will be speaking on Tuesday Nov 24, during the Track From Preclinical to Drug Approval at...
by Adam | Mar 27, 2020 | News
March 26, 2020 04:42 PM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced it has reduced the timeline from biopsy to vaccine to under 4 weeks for its personalized neoantigen...
by Annie De Groot | Feb 3, 2020 | Events
Dr. Anne De Groot will be going to Lisbon, Portugal to attend the European Immunogenicity Platform Symposium from 17-19th Feb. While there, she will be giving a talk on EpiVax’s immunoinformatics platform on Day 2, 18Feb at 2:30PM. The talk will focus on...
